Core Viewpoint - InMode Ltd. is revising its full-year revenue guidance for 2025 due to ongoing market weakness and uncertainty in the U.S. economic outlook, with preliminary second-quarter revenue expected to be between $95.4 million and $95.5 million [3][7]. Financial Results - The company anticipates second-quarter 2025 revenue in the range of $95.4 million to $95.5 million [7]. - The non-GAAP gross margin for the second quarter of 2025 is expected to be between 79% and 80% [7]. - Full-year 2025 revenue guidance has been revised to a range of $365 million to $375 million, down from the previous guidance of $395 million to $405 million [3][7]. Conference Call Details - A conference call to discuss the second-quarter financial results will be held on July 30, 2025, at 8:30 a.m. Eastern Time, featuring key executives including the CEO, CFO, and CTO [4][5]. - Participants are encouraged to pre-register for the call to receive unique dial-in information [5]. Company Overview - InMode is a global provider of innovative medical technologies, focusing on devices that utilize novel radio frequency technology for various medical applications [7][8]. - The company aims to enhance surgical procedures and improve existing treatments through its minimally invasive RF technologies [8].

Core Viewpoint - InMode Ltd. addresses concerns raised by DOMA Perpetual Capital Management regarding its operations, buyback strategy, and management performance, emphasizing its commitment to shareholder value and operational integrity [2][3][5][6]. Buyback Strategy - InMode has executed a share buyback program amounting to $412 million over the last 12 months and $508 million over the past 2.5 years, aiming to return capital to shareholders in a tax-efficient manner [3]. Manufacturing and Supply Chain - The company maintains that its manufacturing operations in Israel are essential due to the proximity to engineering, R&D, and logistics teams, and has successfully delivered products to 90 countries despite ongoing regional conflicts [4]. Sales Performance - The slowdown in North American sales is attributed to macroeconomic factors and financing challenges rather than issues within the sales management team, which is fully staffed and operating professionally [5]. Management Performance - The CEO refutes claims of poor leadership and emphasizes a lean management style, asserting that the Board of Directors will ultimately decide on his performance [6]. Company Overview - InMode is a global provider of innovative medical technologies, specializing in devices that utilize radio frequency technology for various medical fields, including plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology [8].

Core Viewpoint - InMode Ltd. is set to release its financial results for the first quarter of 2025 on April 28, 2025, with preliminary revenue expectations ranging from $77.2 million to $77.5 million and a projected non-GAAP gross margin of 78% to 79% [6][2]. Financial Results - The company anticipates first quarter 2025 revenue to be between $77.2 million and $77.5 million [6]. - The projected non-GAAP gross margin for the same period is expected to be in the range of 78% to 79% [6]. - For the full year 2025, InMode expects revenue to be between $395 million and $405 million [6]. Conference Call Details - A conference call to discuss the first quarter 2025 financial results will take place on April 28, 2025, at 8:30 a.m. Eastern Daylight Time [3]. - Key management personnel, including the CEO, CFO, and CTO, will present during the call [3]. - Participants are encouraged to pre-register for the call to receive unique dial-in information [4]. Company Overview - InMode is recognized as a leading global provider of innovative medical technologies, focusing on devices that utilize novel radio frequency technology [6][7]. - The company aims to enhance surgical procedures and improve existing treatments across various medical fields, including plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology [6][7].